Emerg Infect Dis. 2023 Apr;29(4):686-695. doi: 10.3201/eid2904.221397.
New Zealand (Aotearoa) experienced a Neisseria meningitidis serogroup B epidemic during 1991-2006, and incidence remains twice that of other high-income countries. We reviewed clinical, laboratory, and immunization data for children <15 years of age with laboratory-confirmed invasive meningococcal disease in Auckland, New Zealand, during January 1, 2004-December 31, 2020. Of 319 cases in 318 children, 4.1% died, and 23.6% with follow-up data experienced sequelae. Children of Māori and Pacific ethnicity and those living in the most deprived areas were overrepresented. Eighty-one percent were positive for N. meningitidis serogroup B, 8.6% for serogroup W, 6.3% for serogroup C, and 3.7% for serogroup Y. Seventy-nine percent had bacteremia, and 63.9% had meningitis. In New Zealand, Māori and Pacific children are disproportionately affected by this preventable disease. N. meningitidis serogroup B vaccine should be included in the New Zealand National Immunization Schedule to address this persistent health inequity.
新西兰（奥特亚罗瓦）在 1991 年至 2006 年期间经历了脑膜炎奈瑟菌 B 群流行，其发病率仍然是其他高收入国家的两倍。我们回顾了 2004 年 1 月 1 日至 2020 年 12 月 31 日期间，在新西兰奥克兰，年龄在 15 岁以下的实验室确诊侵袭性脑膜炎球菌病患儿的临床、实验室和免疫接种数据。在 318 名儿童中的 319 例病例中，有 4.1%的患儿死亡，23.6%有随访数据的患儿出现后遗症。毛利族和太平洋族裔以及生活在最贫困地区的儿童的比例过高。81%的患儿为脑膜炎奈瑟菌 B 群阳性，8.6%为 W 群阳性，6.3%为 C 群阳性，3.7%为 Y 群阳性。79%的患儿有菌血症，63.9%的患儿有脑膜炎。在新西兰，毛利族和太平洋族裔儿童受这种可预防疾病的影响不成比例。新西兰国家免疫计划应纳入脑膜炎奈瑟菌 B 群疫苗，以解决这一持续存在的健康不平等问题。
